Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 10, 2014, Pages 1636-1646

  Schmitz, E M H ^a,b,c   Boonen, K ^a   van den Heuvel, D J A ^a   van Dongen, J L J ^b,c   Schellings, M W M ^d   Emmen, J M A ^d   van der Graaf, F ^c,d   Brunsveld, L ^b,c   van de Kerkhof, D ^a,c  

^a CATHARINA HOSPITAL   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c Expert Center Clinical Chemistry Eindhoven   (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

Apixaban; Dabigatran; Drug monitoring; Mass spectrometry; Rivaroxaban

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TEST; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DETERMINATION; DRUG MONITORING; HUMAN; LIMIT OF DETECTION; MEASUREMENT ACCURACY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO; TANDEM MASS SPECTROMETRY; THROMBIN TIME; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; BLOOD CLOTTING; CALIBRATION; CHEMISTRY; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION; QUALITY CONTROL; REFERENCE VALUE; REPRODUCIBILITY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; QUALITY CONTROL; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; THIOPHENES;

EID: 84907863533     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12702     Document Type: Article

References (33)

1. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
2. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-95.
3. Bassand J. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace 2012; 14: 312-24.
4. van Ryn J, Stangier J, Haertter S, Liesenfeld K-H, Wienen W, Feuring M. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
5. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44S-88S.
6. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-47.
7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-47.
8. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-72.
9. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 8: 1493-502.
10. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 2: 308-15.
11. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 2012; 5: 552-8.
12. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of dabigatran on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 2: 283-94.
13. Curvers J, van de Kerkhof D, Stroobants AK, van den Dool E-J, Scharnhorst V. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays. Which assay is helpful? Am J Clin Pathol 2012; 138: 551-8.
14. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-43.
15. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné J-M. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-97.
16. Lange U, Nowak G, Bucha E. The Ecarin Chromogenic Assay - a new method for quantification of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 2003; 33: 184-91.
17. Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008; 130: 446-54.
18. Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, Seifert B, Stricker H, Tsakiris DA, Wuillemin WA. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-8.
19. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants - reasons, methods and current limitations. J Thromb Thrombolysis 2013; 2: 187-94.
20. Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 2011; 32: 267-71.
21. Douxfils J, Dogné JM, Mullier F, Chatelain B, Rönquist-Nii Y, Malmström RE, Hjemdahl P. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 3: 543-9.
22. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg EM, Onelöv L, Rönquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmström RE. Evaluation of coagulation assays versus LC-MS/MS for determination of dabigatran concentration in plasma. Eur J Clin Pharmacol 2013; 11: 1875-81.
23. Rohde G. Determination of rivaroxaban - a novel, oral, direct factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
24. Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J Pharm Biomed Anal 2012; 58: 152-6.
25. EP10-A3: Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline - Third edition. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
26. Guidance for industry. Bioanalytical method validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Vetenary Medicine (CVM), 2001.
27. Schmitz EMH, van den Heuvel D, Boonen K, van Dongen JLJ, Brunsveld L, van de Kerkhof D. Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring. Ned Tijdschr Klin Chem Labgeneesk 2013; 38: 142-4.
28. Liesenfeld K-H, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527-37.
29. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-65.
30. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-99.
31. Wong PC, Pinto DJP, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011; 31: 478-92.
32. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban - an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32: 183-7.
33. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A; Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242-7.